It’s Wednesday at the 2017 JP Morgan Healthcare Conference and the last full day of the meeting. 

SF Streetcar at Pine StIt’s also our last day for a rolling blog; we hope you’ve enjoyed our coverage and commentary this year.

If you want to catch up on what we’ve written about, do check out our posts form Day 1 (Link) and Day 2 of JPM17 (Link).

Yesterday also included some thoughts on the latest Merck pembrolizumab filing announcement in 1L NSCLC, which has certainly had a dramatic impact on the market, even for big pharma (MRK +$4.9B, BMY -$3.3B).

Companies we’ve covered so far include: Celgene, Incyte, Seattle Genetics, Clovis, Puma, BMS, Five Prime, Nektar, Juno and others.

Subscribers can login to read more

This content is restricted to subscribers

Posted by